- Home
- SGHT vs STRO Comparison
SGHT vs STRO Comparison
Compare SGHT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- STRO
- Stock Information
- Founded
- SGHT 2011
- STRO 2003
- Country
- SGHT United States
- STRO United States
- Employees
- SGHT N/A
- STRO N/A
- Industry
- SGHT Medical Specialities
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGHT Health Care
- STRO Health Care
- Exchange
- SGHT Nasdaq
- STRO Nasdaq
- Market Cap
- SGHT 304.4M
- STRO 292.6M
- IPO Year
- SGHT 2021
- STRO 2018
- Fundamental
- Price
- SGHT $4.03
- STRO $2.75
- Analyst Decision
- SGHT Buy
- STRO Strong Buy
- Analyst Count
- SGHT 6
- STRO 7
- Target Price
- SGHT $6.80
- STRO $12.14
- AVG Volume (30 Days)
- SGHT 281.6K
- STRO 888.5K
- Earning Date
- SGHT 11-07-2024
- STRO 11-13-2024
- Dividend Yield
- SGHT N/A
- STRO N/A
- EPS Growth
- SGHT N/A
- STRO N/A
- EPS
- SGHT N/A
- STRO N/A
- Revenue
- SGHT $79,543,000.00
- STRO $160,955,000.00
- Revenue This Year
- SGHT $2.18
- STRO N/A
- Revenue Next Year
- SGHT $8.14
- STRO N/A
- P/E Ratio
- SGHT N/A
- STRO N/A
- Revenue Growth
- SGHT N/A
- STRO 230.90
- 52 Week Low
- SGHT $2.58
- STRO $2.45
- 52 Week High
- SGHT $8.45
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- SGHT 38.25
- STRO 39.12
- Support Level
- SGHT $3.86
- STRO $2.55
- Resistance Level
- SGHT $4.11
- STRO $2.76
- Average True Range (ATR)
- SGHT 0.21
- STRO 0.27
- MACD
- SGHT 0.06
- STRO -0.05
- Stochastic Oscillator
- SGHT 36.26
- STRO 18.51
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.